Gerard Fumo, DO
Hematology & Oncology · Meriden, CTNPI 1770524753
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,341 and has fallen 63.0% since, to $497 in 2025.
Across 124 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$364
- Pfizer$185
- E.r. Squibb & Sons, L.L.C.$147
- Genentech USA, Inc.$132
- AstraZeneca$124
- Novartis$118
- plus $1K from 31 others
Across 2 payments — averaging $1427.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$3K
What the payments were for
- Food & beverage$2,23696%
- Education$914%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 18 | $364 |
| Pfizer | 11 | $185 |
| E.r. Squibb & Sons, L.L.C. | 9 | $147 |
| Genentech USA, Inc. | 10 | $132 |
| AstraZeneca(2 entities) | 7 | $124 |
| Novartis | 6 | $118 |
| Merck | 6 | $95 |
| Astellas Pharma US Inc | 4 | $86 |
| Coherus Oncology, Inc. | 4 | $85 |
| Bayer | 4 | $82 |
| Sanofi | 4 | $82 |
| Johnson & Johnson(2 entities) | 5 | $74 |
| GSK | 2 | $66 |
| Ipsen Biopharmaceuticals, Inc | 2 | $59 |
| Incyte Corporation | 3 | $57 |
| Dendreon Pharmaceuticals LLC | 2 | $51 |
| AMAG Pharmaceuticals, Inc. | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Seagen Inc. | 2 | $36 |
| Amgen | 2 | $35 |
| Exelixis Inc. | 2 | $35 |
| Taiho Oncology, Inc. | 1 | $34 |
| Genmab U.S., Inc. | 1 | $31 |
| Boehringer Ingelheim | 1 | $31 |
| Dova Pharmaceuticals | 2 | $29 |
| Advanced Accelerator Applications | 1 | $25 |
| Eisai Inc. | 1 | $21 |
| Array Biopharma Inc | 1 | $21 |
| Mylan Institutional Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Mirati Therapeutics, Inc. | 1 | $18 |
| Rigel Pharmaceuticals, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Aurobindo Pharma USA, Inc. | 1 | $14 |
| EMD Serono, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$2,327 in reported general payments places this provider in the 55th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 65 | $1,166,620 |
| JakafiRuxolitinib Phosphate | 37 | $675,273 |
| XtandiEnzalutamide | 41 | $601,301 |
| IbrancePalbociclib | 21 | $339,472 |
| TagrissoOsimertinib Mesylate | 19 | $321,319 |
| EliquisApixaban | 249 | $232,895 |
| ImbruvicaIbrutinib | 13 | $191,769 |
| Abiraterone Acetate | 111 | $191,580 |
| GilotrifAfatinib Dimaleate | 15 | $172,729 |
| CalquenceAcalabrutinib Maleate | 12 | $163,099 |
| XareltoRivaroxaban | 146 | $151,202 |
| VotrientPazopanib Hcl | 12 | $102,305 |
| Atovaquone | 25 | $7,214 |
| Potassium Chloride | 89 | $3,240 |
| Anastrozole | 210 | $3,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $364 | $1,166,62065 claims |
| Incyte CorporationJakafi | $57 | $675,27337 claims |
| Astellas Pharma US IncXtandi | $86 | $601,30141 claims |
| PfizerIbrance, Eliquis | $185 | $572,368270 claims |
| AstraZenecaTagrisso, Calquence | $124 | $484,41831 claims |
| Boehringer IngelheimGilotrif | $31 | $172,72915 claims |
| Johnson & JohnsonXarelto | $74 | $151,202146 claims |
| NovartisVotrient | $118 | $102,30512 claims |
| Lilly USA, LLCOlanzapine | $15 | $87651 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in Meriden
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
- Walid ShaibNew Haven$217K
- Madhavi GorusuHartford$207K
- Dinesh KapurNorwich$201K
- Scott HuntingtonNew Haven$163K
- Nataliya UbohaNew Haven$124K
- Michael CecchiniNew Haven$103K
- Justine RyuOrange$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.